- Sustained enforcement against misleading GLP-1 marketing claims by the FDA against regulated companies.
- Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.
FDA warns of counterfeit GLP-1 drugs and illegal semaglutide/tirzepatide
What happened
The FDA warned that illegally marketed semaglutide and tirzepatide could contain harmful ingredients, or too much, too little, or none of the advertised active ingredient. This warning follows reports that the popularity of GLP-1 medications has fueled counterfeit Ozempic and fraudulent compounded products. Federal prosecutors announced charges in September 2026 against two men accused of smuggling counterfeit Ozempic from China.
From savingadvice.com
Why it matters
The high cost of legitimate GLP-1 treatment makes consumers vulnerable to counterfeit products. The presence of these illicit drugs, which are often sold at discounted prices, poses risks to consumer health and the integrity of the pharmaceutical market.
Eli Lilly has warned the FDA about black market drug sales, while U.S. Customs and Border Protection has intercepted shipments of illicit GLP-1 drugs.
From savingadvice.com
Who's involved
- FDARegulatory agency issuing warnings about illegal drug sales.
- General Administration of CustomsChinese ministry-level administrative agency involved in the smuggling of counterfeit products.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Novo NordiskSpeculative
Counterfeiting might threaten Novo Nordisk's market share and brand reputation.
- General Administration of CustomsSpeculative
Regulatory action might increase the operational costs and enforcement burden for the General Administration of Customs.